GET DAILY SIGNALSWhy Is STAAR Surgical Company (STAA) Stock Down 4.19% Today?
Key Takeaways
- STAA shares fell about 4.19% to $25.60, giving back gains after a post-earnings surge earlier in the week.
- The primary driver is profit-taking following the company's third-quarter report, which beat on revenue but revealed a deepening margin squeeze.
- Secondary pressure comes from manufacturing yield constraints, supply limitations in China, and the absence of formal guidance.
- The pullback follows two volatile sessions in which the stock spiked roughly 8% after earnings before fading.
- Traders are watching whether fourth-quarter gross margins improve and whether Chinese supply catches up to demand.
- For deeper context, explore Price Targets, Earnings, and Forecast pages for STAA.
- You can also discover top-performing strategies for STAA and thousands of other tickers on the Trending AI Robots page.
Opening Summary
STAAR Surgical Company (STAA), a medical device maker known for its implantable Collamer lenses (ICL) used in vision-correction surgery, traded lower on Thursday, down about 4.19% to $25.60 after closing the prior session at $26.72. The decline comes just days after the company reported third-quarter results that beat Wall Street's revenue and adjusted-earnings expectations but also exposed mounting profitability headwinds. Investors appear to be consolidating the stock's sharp post-earnings advance, with margin concerns and supply constraints outweighing an otherwise accelerating demand story.
Profit-Taking After the Earnings Surge
The sharpest driver of Thursday's move appears to be a classic post-earnings pullback. STAA shares rallied roughly 8% on November 4 after the company released third-quarter numbers, extending a multi-week advance off its lows. With the stock up sharply in a short window, short-term traders and longer-term holders alike took the opportunity to lock in gains. The result is a session of consolidation in which the bullish headline earnings momentum has given way to a more measured reassessment of the quarter's quality.
Margin Squeeze and Supply Constraints
Beneath the headline beat, the third-quarter report carried bearish signals. Gross margin slipped to 70.9% from 74.5% in the second quarter, while adjusted EBITDA fell for a second consecutive quarter. Management attributed the erosion to temporary factors — higher unit costs tied to a low-production period during an ERP rollout, elevated freight expenses, tariffs on U.S.-made lenses shipped to China, and larger provisions for expiring inventory. Critically, STAA could not fully meet lens demand during the quarter, meaning all of its China revenue growth came from higher average selling prices rather than increased unit volume. Manufacturing yields remain below historical levels, leaving the durability of volume expansion as an open question for investors.
Lack of Formal Guidance
Adding to the caution, STAA continues to offer no formal financial guidance. Management signaled that fourth-quarter gross margin should improve sequentially and that real unit-cost improvement is expected in 2027, but also flagged an anticipated seasonal sequential decline in China revenue during the fourth quarter. Without explicit forward targets, the market is left to weigh the company's improving demand narrative against ongoing execution uncertainty.
Market Context and Trading Activity
Thursday's decline unfolded on active trading, consistent with elevated volume seen throughout the post-earnings period. The move reflects stock-specific factors rather than broad market stress, as the pullback centered on STAA's own margin and supply narrative. The stock's volatility is not unusual — STAA has a history of large daily swings, and the current session marks a reversal of the earnings-driven gains that pushed shares to multi-week highs. Technical traders are now watching whether the stock can hold support near its recent breakout levels after surrendering a portion of the rally.
What Comes Next for STAA
Looking ahead, investors will focus on whether STAA can deliver the promised fourth-quarter gross-margin improvement and whether Swiss-based manufacturing capacity catches up to underlying Chinese demand. Additional catalysts include the expected start of first-in-human trials for two next-generation presbyopia lenses, continued EVO+ adoption in China, and the execution of the company's newly authorized $50 million share-repurchase program. Risks remain, including lingering supply constraints, margin pressure that may persist into 2027, and the absence of formal guidance that leaves the growth trajectory subject to interpretation. Broader sector dynamics, including the ongoing shift from laser-based to lens-based vision correction, will also shape sentiment in the quarters ahead.
Trending AI Robots
Tickeron offers hundreds of AI-powered trading bots that cover thousands of tickers, but only the strongest performers under current market conditions are featured in its curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving investors a range of approaches for navigating volatile names like STAA. Explore the Trending AI Robots page to discover which strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
STAA in upward trend: 10-day moving average moved above 50-day moving average on October 28, 2026
The 10-day moving average for STAA crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 79%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on STAA as a result. In 74 of 104 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 71%.
STAA moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +8.94% 3-day Advance, the price is estimated to grow further. Considering data from situations where STAA advanced for three days, in 196 of 278 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
The Aroon Indicator entered an Uptrend today. In 85 of 139 cases where STAA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 61%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
STAA broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 31 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. STAA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 89 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.667) is normal, around the industry mean (4.976). STAA's P/E Ratio (334.000) is considerably higher than the industry average of (41.031). Projected Growth (PEG Ratio) (2.060) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (3.331) is also within normal values, averaging (56.876).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STAA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a designer of implantable lenses for the eye and delivery systems used to deliver lenses into the eye
Industry PharmaceuticalsOther
Advertisement